Clinical trial · Observational
Prognostic Value of miR-21 and miR-486 in Pulmonary Nodule Surgery
Predictive Value of miR-21 and miR-486 Expression in Patients Undergoing Clock-Guided Minimally Invasive Surgery for Pulmonary Nodules
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study prospectively evaluated the prognostic value of microRNA-21 (miR-21) and microRNA-486 (miR-486) expression in patients with pulmonary nodules who underwent clock-guided minimally invasive surgery. The study aimed to determine if high expression levels of these miRNAs in resected nodule tissue correlate with poorer clinical outcomes, including larger residual tumor size, higher metabolic activity, and shorter overall and progression-free survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Nodule Cm | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clock-Guided Minimally Invasive Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- High miR-21/miR-486 Expression Group (n=62)
- description
- Patients whose resected pulmonary nodule tissue showed expression of miR-21 greater than a 2.5-fold change or miR-486 greater than a 1.8-fold change compared to reference levels, as determined by ROC curve analysis.
- interventionNames
- Procedure: Clock-Guided Minimally Invasive Surgery
- label
- Low miR-21/miR-486 Expression Group (n=76)
- description
- Patients whose resected pulmonary nodule tissue showed expression of miR-21 less than or equal to a 2.5-fold change and miR-486 less than or equal to a 1.8-fold change compared to reference levels.
- interventionNames
- Procedure: Clock-Guided Minimally Invasive Surgery
Primary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- Assessed up to January 2022 (up to 24 months of follow-up)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years; * Single or multiple pulmonary nodules confirmed by imaging; * Pathologically confirmed or highly suspected malignancy; * Eligible for clock-guided minimally invasive surgery; * No contraindications to surgery; * Signed informed consent. Exclusion Criteria: * Uncontrolled comorbidities (e.g., hypertension \>180/110 mmHg, HbA1c \>9%); * Inoperable status; * Benign nodules confirmed by pathology; * Severe organ dysfunction (e.g., LVEF \<40%, eGFR \<30 mL/min); * Immunosuppressive therapy; * Recent anticancer treatment (\<3 months); * Lost to follow-up.
References
Publications (0)
Data not yet available